p53 Inhibits Adriamycin-Induced Down-Regulation of Cyclin D1 Expression in Human Cancer Cells
- 25 January 2002
- journal article
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 290 (3) , 1101-1107
- https://doi.org/10.1006/bbrc.2001.6314
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Expression of cell cycle markers in colorectal carcinoma: Superiority of cyclin A as an indicator of poor prognosisInternational Journal of Cancer, 1999
- CDK inhibitors: positive and negative regulators of G1-phase progressionGenes & Development, 1999
- The cyclin D1 gene is a target of the β-catenin/LEF-1 pathwayProceedings of the National Academy of Sciences, 1999
- β-Catenin regulates expression of cyclin D1 in colon carcinoma cellsNature, 1999
- Inhibition of basal and mitogen-stimulated pancreatic cancer cell growth by cyclin D1 antisense is associated with loss of tumorigenicity and potentiation of cytotoxicity to cisplatinum.Journal of Clinical Investigation, 1998
- Novel combination therapy for human colon cancer with adenovirus-mediated wild-typep53 gene transfer and DNA-damaging chemotherapeutic agentInternational Journal of Cancer, 1997
- p53, the Cellular Gatekeeper for Growth and DivisionCell, 1997
- Transforming p21 Mutants and c-Ets-2 Activate the Cyclin D1 Promoter through Distinguishable RegionsJournal of Biological Chemistry, 1995
- Cancer Therapy Meets p53New England Journal of Medicine, 1994
- Molecular regulation of apoptosis: Genetic controls on cell deathCell, 1993